RG-6061

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRG-6061
Drug Alias NameRO-7070179SPC-2968EZN-2968RG-6061
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionHypoxia-inducible factor 1 alpha inhibitors
TargetsHypoxia-inducible factor 1 alpha
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, HepatocellularCarcinoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnzon Pharmaceuticals IncF. Hoffmann-La Roche LtdNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsCarcinoma, HepatocellularCarcinoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A